Clinical research increasingly depends on electronic systems to support core trial documentation, data handling, and regulated workflows. That shift has made the relationship between clinical trial conduct and electronic record controls more immediate. Organizations can no longer think about Good Clinical Practice (GCP) and 21 Code of Federal Regulations (CFR) Part 11 as separate concerns, especially when FDA-regulated trial records are created, maintained, modified, or stored electronically.
GCP establishes broad expectations for the ethical design, conduct, recording, and reporting of clinical trials involving human participants, while 21 CFR Part 11 focuses specifically on the controls needed to maintain trustworthy electronic records and electronic signatures. Together, these frameworks help clinical research organizations protect participants, support data integrity, and demonstrate regulatory compliance throughout Food and Drug Administration (FDA)-regulated clinical trials.
By understanding how these requirements work together, organizations can use electronic systems across regulated clinical research to strengthen compliance and support data integrity more effectively.
What is Good Clinical Practice and why does it matter?
GCP is the internationally recognized quality standard for designing, conducting, recording, and reporting clinical trials involving human participants. Its purpose is to protect participant rights and safety while helping ensure clinical trial data are credible and suitable for regulatory review.
At its core, GCP connects ethical conduct with operational discipline, creating a framework for oversight and accountability across the clinical trial lifecycle. It requires organizations to conduct trials under appropriate oversight and maintain records that accurately reflect what happened during the study. These expectations apply across the clinical research ecosystem:
- Sponsors are responsible for overseeing trial quality and ensuring the protocol, systems, processes, and partners supporting the study remain appropriately managed and aligned with GCP.
- Contract research organizations (CROs) are responsible for carrying out delegated responsibilities and ensuring their work still aligns with applicable GCP requirements.
- Institutions and research sites are responsible for conducting trials according to the protocol, protecting participants, maintaining essential documents, and ensuring site staff are appropriately trained.
Documentation is central to GCP compliance because complete records show how the trial was conducted and support accountability. Accurate, complete, and accessible records support oversight, inspection readiness, and regulatory review. And when those records are electronic, organizations must also ensure the supporting systems preserve their integrity and can withstand that regulatory review.
What is 21 CFR Part 11 and who must comply?
21 CFR Part 11 is the FDA regulation that establishes requirements for electronic records and electronic signatures, helping ensure they are trustworthy, reliable, and generally equivalent to paper records and handwritten signatures.
Common systems subject to 21 CFR Part 11 requirements may include:
- eRegulatory platforms used to manage study documentation and workflows.
- eConsent solutions used to capture participant consent electronically.
- Electronic investigator site files (eISFs) used by research sites.
- Electronic trial master files (eTMFs) used by sponsors and CROs.
- Clinical data management systems used to collect and manage study data.
Organizations must be prepared to demonstrate 21 CFR Part 11 compliance when electronic systems are used to create, maintain, modify, or store records required by FDA regulations. This includes not only the technology itself, but also the organizational controls needed to ensure the system is used appropriately.
How 21 CFR Part 11 supports Good Clinical Practice requirements
GCP and 21 CFR Part 11 have different scopes, but they share several important goals. Both are designed to support participant safety, strengthen data integrity, and reinforce confidence in clinical trial results.
GCP establishes the broader framework for how trials should be conducted and documented, while Part 11 provides specific controls for electronic records and electronic signatures used in FDA-regulated environments. When implemented effectively, Part 11 controls help organizations meet GCP documentation expectations by protecting the integrity and traceability of electronic records throughout the study lifecycle.
For example:
- Access controls help ensure regulated records can be accessed and acted on only by authorized users.
- Audit trails provide a traceable history of changes to electronic records over time.
- Electronic signatures help establish clear user accountability for regulated actions taken within the system.
Together, these capabilities support the recordkeeping discipline required under GCP.
Part 11 compliance does not replace GCP compliance. Instead, it supports GCP by helping ensure electronic documentation can stand up to monitoring, audits, and FDA inspections.
Why 21 CFR Part 11 compliance is essential for clinical trial data integrity
Data integrity in clinical research means data remain complete, accurate, consistent, and reliable over time. It’s central to GCP because clinical trial decisions depend on credible, well-documented information. If records are incomplete, altered without appropriate traceability, or difficult to retrieve, organizations may struggle to demonstrate the quality and reliability of the trial.
21 CFR Part 11 compliance helps protect regulated data through technical and procedural controls. These controls reduce the risk of unauthorized changes, documentation gaps, and other issues that can undermine the reliability of regulated data.
Compliant electronic systems also support ALCOA+ principles (i.e., data integrity principles requiring data to be attributable, legible, contemporaneous, original, accurate, and complete). In practical terms, that means an organization should be able to show how a record was handled over time and whether it has been preserved in a reliable form.
Without appropriate Part 11 controls, electronic records may be more difficult to defend during an inspection, even when the underlying clinical activities were performed correctly.
Electronic records and electronic signatures under 21 CFR Part 11
Electronic records used in regulated research must be created, maintained, secured, and retained in a way that preserves their reliability. Organizations should be able to retrieve records when needed and show that those records remain protected and traceable throughout their lifecycle.
Electronic signatures carry their own accountability expectations, because they must be uniquely linked to individual users and shouldn’t be reused by or reassigned to others. When a person applies an electronic signature, the system and supporting procedures should clearly link that action to the individual signer and its regulatory significance.
Record retention, accessibility, and traceability are especially important in clinical research. During an audit or inspection, organizations may need to produce records quickly and show they’ve been maintained appropriately. A system that stores records electronically but makes them difficult to retrieve, review, or interpret can create compliance risk.
Common challenges often stem from weak controls, inconsistent processes, and gaps in system validation. For example, access settings may allow users to modify records more broadly than intended, site teams may follow different document-handling steps for the same study, or system changes may not be validated before they affect regulated records.
Audit trails and their role in Good Clinical Practice compliance
Audit trails are records of activity within an electronic system. They document how electronic records are created, changed, approved, and otherwise acted on throughout the record lifecycle. In regulated clinical research, audit trails are critical because they make record activity easier to reconstruct and evaluate over time.
As a component of 21 CFR Part 11 compliance, audit trails help provide transparency and establish accountability within regulated electronic systems. They allow organizations to trace changes back to the responsible user and the underlying record history. This level of traceability supports GCP by helping demonstrate records are reliable and haven’t been altered without appropriate documentation.
Audit trail review can strengthen inspection readiness and support regulatory oversight by helping organizations detect emerging compliance issues before they become inspection findings.
Common audit trail deficiencies often reflect incomplete capture or weak review and documentation practices. For example, a key system may fail to record changes to consent records, or teams may review audit trail data without documenting what was assessed or resolved.
Common misconceptions about Good Clinical Practice and 21 CFR Part 11
Several misunderstandings can make it harder for organizations to assess their compliance obligations accurately.
Common misconceptions include:
- Part 11 compliance automatically equals GCP compliance: It doesn’t. Part 11 is one component of compliance in electronically enabled research environments, addressing the controls needed for electronic records and electronic signatures, but it doesn’t cover the full scope of GCP requirements. GCP covers the broader responsibilities involved in conducting and overseeing clinical trials responsibly.
- Vendors are responsible for compliance: While vendors may provide systems designed to support regulated use, organizations still remain responsible for validating those systems and governing how they’re used in practice.
- Electronic signatures or audit trails alone guarantee compliance: These features are important, but they don’t guarantee compliance on their own. They must be supported by the broader processes and governance that make compliant system use sustainable.
During inspections, organizations often fall short when documentation, training, validation, and oversight aren’t managed consistently. For example, teams may rely on incomplete training records, operate with outdated validation materials, or lack a clear process for escalating oversight issues when they arise.
Best practices for maintaining Good Clinical Practice and 21 CFR Part 11 compliance
Maintaining compliance requires more than selecting the right technology—it depends on a coordinated approach that connects technology, oversight, and day-to-day execution.
Best practices include:
- Developing clear standard operating procedure (SOP) and governance processes for managing electronic systems and regulated records, including how issues are reviewed and escalated.
- Training personnel on both GCP requirements and the Part 11 controls relevant to the systems they use, with refreshers as responsibilities or processes change.
- Periodically reviewing systems and compliance controls to identify and address emerging compliance risks before they become larger issues.
- Building inspection and audit readiness into routine operations so regulated records and supporting controls can be explained clearly when needed.
Strengthening compliance across electronic clinical research systems
GCP and 21 CFR Part 11 work together to support participant safety, data integrity, and inspection readiness across electronic clinical research. GCP establishes the broader expectations for participant protection, trial conduct, oversight, and documentation, while Part 11 provides specific requirements for maintaining trustworthy electronic records and electronic signatures in FDA-regulated environments.
As clinical research continues to rely on electronic systems, organizations need a clear strategy for aligning their technology with the oversight required to use it well. When implemented effectively, 21 CFR Part 11 compliance strengthens data integrity, supports GCP documentation expectations, and helps sponsors, CROs, institutions, and research sites sustain more consistent compliance across electronic trial operations.
Want to learn more? Check out this overview of Advarra’s Good Clinical Practice solutions or contact us to ask an expert a specific question.
